Artivion
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Artivion (AORT) | 1.04B | -354.33 | 2.33 | 0.00% |
| Abbott Laboratories (ABT) | 172.35B | 32.23 | 3.37 | 2.45% |
| Medtronic (MDT) | 113.18B | 21.79 | 2.25 | 3.22% |
| Stryker Corp (SYK) | 106.38B | 28.74 | 4.43 | 1.25% |
| Boston Scientific (BSX) | 61.93B | 17.30 | 2.48 | 0.00% |
| Edwards Lifesciences (EW) | 49.12B | 49.54 | 4.63 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 63.0% below Morningstar's fair value estimate.
Fair value
Artivion Inc may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 38% discount to our quantitative fair value estimate of $34.65 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's balance sheet bolsters our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of 2.1 sits in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.
On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.4%, for example, sits in the bottom 45% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Artivion discussion 0 comments